New blood thinner could be safer for sepsis patients on dialysis
NCT ID NCT07518303
First seen Apr 21, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This study tests whether a newer blood thinner, nafamostat mesylate, works as well as the standard citrate during continuous kidney dialysis in people with sepsis-related kidney injury. About 1,162 adults will be randomly assigned to receive one of the two drugs. The main goal is to see if nafamostat is not worse than citrate at preventing death, need for ongoing dialysis, or lasting kidney damage at 30 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.